Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Osteo Arthritis Knee
Interventions: active tDCS paired with active MBM, sham tDCS paired with active MBM, active tDCS paired with sham MBM, sham tDCS paired with sham MBM; Device
Lead sponsor: University of Arizona; Other
Eligibility: 50 Years to 85 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm, Malignant Lung Neoplasm
Interventions: Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Anxiety
Interventions: Mayo Clinic Anxiety Coach; Device
Lead sponsor: Stephen Whiteside; Other
Eligibility: 7 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Colorectal Cancer
Interventions: bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin; Biological · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
Interventions: 7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.; Other
Lead sponsor: Sunnybrook Health Sciences Centre; Other
Eligibility: 18 Years and older
Enrollment: 3,622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Healthy Volunteers
Interventions: Glasdegib, Rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Interventions: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more

Conditions: Reduction of Hypertrophic Skin Scarring
Interventions: PF-06473871; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 36
States / cities: Irvine, California • La Jolla, California • Walnut Creek, California + 20 more

Conditions: Relapsed Acute Myelogenous Leukemia
Interventions: Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: 41 Ca; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Livermore, California

Conditions: Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K, Food Effect of ASP015K
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Perinatal Care
Interventions: Pulsenmore ES home ultrasound device; Device
Lead sponsor: PulseNmore; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Boston, Massachusetts + 1 more

Conditions: Solid Tumors
Interventions: E7080, Comparator Drug, Comparator Drug: Sorafenib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Torrance, California • Chicago, Illinois • Detroit, Michigan

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: rivogenlecleucel, rimiducid, Cyclophosphamide, haplo-HSCT; Biological · Drug · Procedure
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Anemia, Multiple Myeloma, Plasma Cell Neoplasm
Interventions: epoetin alfa; Biological
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stroke, Transient Ischemic Attack (TIA)
Interventions: CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy); Genetic
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infections
Interventions: lopinavir/ritonavir plus maraviroc; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Caregiving for Cancer
Interventions: Psychosocial Intervention for Parental Caregivers of AYA with Cancer; Behavioral
Lead sponsor: Zeba Ahmad, Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide, bortezomib, thalidomide, melphalan, autologous stem cell transplant; Drug · Procedure
Lead sponsor: Margarida Magalhaes-Silverman; Other
Eligibility: 65 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hodgkin Lymphoma
Interventions: Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Echocardiography, Blood Collection, Symptoms Questionnaire; Diagnostic Test · Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2037
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: apimostinel, Placebo; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Aging, HIV
Interventions: Weekly Group Skills, One-time Trifold Brochure titled "HIV: 50 Years or Older"; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Home-based tDCS and Mindfulness-based Meditation for Self-management of Clinical Pain and Symptoms

Symptom Management to Improve Completion of Patient-reported Outcome Measures

Youth Mayo Clinic Anxiety Coach Pilot Study

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Investigation of Sleep in the Intensive Care Unit

Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Pulsenmore ES Device, Efficacy and Safety Assessment

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Adapting Psychosocial Resiliency Intervention for Parents of Adolescents and Young Adults With Cancer

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Cardiotoxicity of Cancer Therapy (CCT)

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

Cognitive Behavior Therapy (CBT)-Based Group Intervention to Reduce Inflammation in Older People With HIV